



Dialysis & Nephrology DIGEST

A monthly report by Benesch on the
Dialysis & Nephrology Industry

In This Issue

PAGE 2

Calendar of Events

PAGE 6

Nephrology and Dialysis

Byonyks receives 510(k) clearance for new dialysis machine

PAGE 7

Nation's Kidney Care Community Urges Legislators to Address Growing Kidney Disease Epidemic Impacting Nearly 40 Million Americans

PAGE 8

Benesch: OH bill banning non-compete agreements would have 'detrimental effect' on state businesses

Northwest Kidney Centers says proposed cuts to Medicare, Medicaid 'matter of life or death' for patients

PAGE 9

AKF Kidney Action Summit urged Congress to pass legislation protecting living donors

Members of Congress issue resolution demanding return of public consultations for HHS rules

MIPS improvement activities relating to DEI suspended by CMS; permanent deletion likely

PAGE 10

Report: U.S. import tariffs negatively affecting nephrology, urology market

Fresenius confirms financial outlook after posting strong financial results in Q1

DaVita beats Wall Street expectations for Q1 profit driven by dialysis demand

PAGE 11

DaVita CEO defends AI investments; says technology is future of dialysis sector

DaVita community care report showcases progress toward ESG goals

PAGE 12

Union's health benefits fund sues DaVita, Fresenius for conspiring to inflate treatment costs

DaVita facing two possible class actions relating to data stolen during cyberattack

Interwell Health recognized as among best places to work in healthcare

PAGE 13

North Carolina nephrology practice cited for innovative value-based kidney care

Healthy.io acquires Labrador Health to enhance at-home kidney diagnostics portfolio

Novartis' \$800M acquisition of Regulus includes drug to treat ADPKD

PAGE 14

Study underscores significant electricity costs for patients with home dialysis units

ASN introducing centers of excellence to serve as models for home dialysis care

American Kidney Fund identifies significant racial, ethnic disparities in progression, treatment of ADPKD

PAGE 15

VAC, ASC and Office-Based Labs

Interventional radiologists call for higher Medicare reimbursements for high-cost disposables

Medicare reimbursement for coronary revascularization at ASCs improving, but uptake remains low

Dialysis & Nephrology DIGEST



Please contact us if you would like to post

information regarding our upcoming events or if you'd like to guest author an article for this newsletter.

sdowning@beneschlaw.com

jgreis@beneschlaw.com

jcilek@beneschlaw.com

Calendar of Events

JUNE 9–10, 2025

AMGA 2025 Value Roundtable Summit

Washington, DC

For more information, please click [here](#).

JUNE 11, 2025

AMGA Capitol Hill Day

Washington, DC

For more information, please click [here](#).

AUGUST 12–17, 2025

Nephrology Business Leadership Conference

Plano, TX

For more information, please click [here](#).

SEPTEMBER 17–19, 2025

RHA Annual Conference

Orlando, FL

For more information, please click [here](#).

SEPTEMBER 17–19, 2025

RHA Annual Conference

Orlando, Florida

[Disney's Contemporary Resort](#)

The RHA Annual Conference brings together dialysis professionals, industry leaders, and vendors from across the U.S., offering valuable education, expert insights, and networking opportunities to support the entire renal care community.

For more information, please click [here](#).

SEPTEMBER 26–28, 2025

ANNA: 2025 Nephrology Nursing Summit

Charlotte, NC

For more information, please click [here](#).

SEPTEMBER 30–OCTOBER 3, 2025

Becker's Healthcare: 10th Annual Health IT + Digital Health + RCM Conference

Chicago, IL

For more information, please click [here](#).

OCTOBER 2–4, 2025

7th Annual Therapeutic Apheresis Academy

UVA Pinn Hall Conference Center

Charlottesville, Virginia

For more information, please click [here](#).

NOVEMBER 3–4, 2025

Becker's 4th Annual Fall 2025 Payers Issue Roundtable

Chicago, IL

For more information, please click [here](#).

NOVEMBER 3–6, 2025

Becker's Healthcare: 13th Annual CEO + CFO Roundtable

Chicago, IL

For more information, please click [here](#).

NOVEMBER 5–9, 2025

ASN: Kidney Week 2025

Houston, TX

(Call for Abstracts Deadline May 21)

For more information, please click [here](#).

MARCH 19–21, 2026

2026 OEIS Scientific Meeting

Las Vegas, NV *(details to come)*

OCTOBER 21–25, 2026

ASN: Kidney Week 2026

Denver, CO

For more information, please click [here](#).

continued on next page



Benesch Healthcare+ Fifth Annual Nephrology and Dialysis Conference

Thursday, June 26, 2025

8:00 A.M. –5:00 P.M.

Cocktail reception to follow

The Sheraton Grand Riverwalk Chicago

301 East North Water Street | Chicago

Please join us for this full-day conference addressing business and legal issues facing nephrology and dialysis providers. Hear from industry leaders discussing current and future trends in care delivery, business and payment models and legal and regulatory issues.

Click [HERE](#) to register.

A block of guest rooms has been reserved for attendees at the Sheraton Grand for \$299/night + tax. To reserve a room at the negotiated price, please click [HERE](#) by June 4.

Please contact MEGAN THOMAS, Director of Client Services (mthomas@beneschlaw.com) for more information about this event as well as exhibitor and sponsorship opportunities.

If your organization is interested in Exhibitor Hall opportunities, please click [HERE](#).

**No CME or CLE available.*

AGENDA

8:00–8:45

Registration and Breakfast in Exhibitor Hall

8:45–9:00

Opening Remarks

SCOTT DOWNING AND JASON GREIS, Partners,
Benesch Healthcare+

9:00–9:30

Keynote Address

KEITH BELLOVICH, D.O., President, *Renal Physicians Association*

9:30–10:15

Healthcare Private Equity Investment: Happy Days or Headwinds

Moderator:

JASON GREIS, Partner, *Benesch Healthcare+*

Presenters:

SCOTT KREMEIER, Managing Director, *Piper Sandler*

DOUG SIMPSON, President, *Panoramic Health*

PRABIR ROY-CHAUDHURY MD, PhD, FASN

Drs Ronald and Katherine Falk Eminent Professor and
Co-Director, *UNC Kidney Center*

President, American Society of Nephrology

ROBERT PROVENZANO, MD, CEO, *Innocura*

(continued on next page)

AGENDA

Benesch Healthcare+ Fifth Annual Nephrology and Dialysis Conference

10:15–10:30 **Break**

10:30–11:15

Research Opportunities in Nephrology and Dialysis

Moderator:

LAURI COOPER, Counsel, *Benesch Healthcare+*

Presenters:

BERNARD V. FISCHBACH, MD, CCRP, *Dallas Nephrology Associates*

JAN WALTER, President, *Frenova*

NANCY CIPPARRONE, Director of Research, *Nephrology Associates of Northern Illinois and Indiana*

11:15–12:00

The Future of Kidney Transplantation

Moderator:

JAKE CILEK, Partner, *Benesch Healthcare+*

Presenters:

MICHAEL A. REES, M.D., PhD., *UToledo Health*

MICHELLE A. JOSEPHSON, M.D., *University of Chicago Medicine Transplant Institute*

HARRY E. WILKINS, III, MD, MHCM, President & CEO, *Gift of Hope Organ & Tissue Donor Network*

SUNEEL UDANI, M.D., *Nephrology Associates of Northern Illinois and Indiana*

12:00–12:45 **Networking Lunch**

12:45–1:30

Keynote Lunch: 2025 Update on Federal Kidney Policy

TOM DUVALL, Division Director, *CMS Innovation Center*

1:30–2:15

Artificial Intelligence in Medicine

Moderator:

NICK ADAMSON, Associate, *Benesch Healthcare+*

Presenters:

GILBERT VILLAFOR, Partner, *Benesch*

STEPHANIE TOTH-MANIKOWSKI, MD, National Senior Director, *Healthmap Solutions*

SARAVAN BALAMUTHUSAMY, Founder, *OptMyCare*

KATHRIN ZAKI, Managing Associate, *Benesch*

2:15–3:00

As the Dust Settles on Current VBC Models, What Comes Next?

Moderator:

NESKO RADOVIC, Senior Managing Associate, *Benesch Healthcare+*

Presenters:

PHIL SARNOWSKI, Senior Vice President, Business Transformation, *U.S. Renal Care*

BASSEM MIKHAEL, M.D., Chief Medical Officer for Nephrology, *Somatus*

SAM DANIEL, Chief Strategy Officer, *Monogram Health*

ERICA MALTBY, Regional President, *Strive Health*

TIMOTHY PFLEDERER, M.D., Chief Medical Officer, *Evergreen Nephrology*

3:00–3:15 **Break**

3:15–4:15

Innovative Kidney Care Companies to Know

Moderator:

CHRIS DEGRANDE, Partner, *Benesch Healthcare+*

Companies:

Byonyks Medical Devices—FARRUKH USMAN, Founder and CEO

Laminate Medical—KENT BUTLER, Head of US Sales
Mozarc Medical—MIKE SERLE, Senior Director, Global Medical & Clinical Affairs

Neway Labs—BRYAN THOMPSON, Chief Executive Officer

Phraxix—ALEX YEVLIN, Chief Executive Officer

VenoStent—TIMOTHY BOIRE, Chief Executive Officer

Vivance—MANDAR GORI, Chief Business Officer

4:15–5:00

An Update on Federal and State Laws to Regulate Non-Compete Covenants

J. SCOTT HUMPHREY, Partner, *Benesch*

5:00–6:30 **Cocktail Reception**



Please contact MEGAN THOMAS, Director of Client Services (mthomas@beneschlaw.com) for more information about this event as well as exhibitor and [sponsorship opportunities](#).

Exhibitor and Sponsorship Opportunities Benesch Healthcare+ Fifth Annual Nephrology and Dialysis Conference

Thursday, June 26, 2025

8:00 A.M. –5:00 P.M.

Cocktail reception to follow

The Sheraton Grand Riverwalk Chicago

301 East North Water Street | Chicago

Conference Registration \$250

Please register and pay [HERE](#).

Break Sponsorships \$2000 (two slots)

- Logo
- Spotlight
- 4 free registrations
- List of attendees week before

To purchase a break sponsorship,
please register and pay [HERE](#).

Exhibitor Space \$1000

- Logo
- Overview of company within handout
- 2 free conference registrations
- List of attendees week before

To purchase an exhibitor table,
please register and pay [HERE](#).

Breakfast Sponsor \$3500

- Logo
- Spotlight with free plug
- 8 conference registrations
- List of attendees week before

To purchase a breakfast sponsorship,
please register and pay [HERE](#).

Lunch Sponsor \$4000

- Logo
- Spotlight with free plug
- 8 conference registrations
- List of attendees week before

To purchase a lunch sponsorship,
please register and pay [HERE](#).

Cocktail Reception Sponsor \$6000

- Logo
- Spotlight with free plug
- Decorate space with signage
- 8 conference registrations
- List of attendees week before

To purchase a cocktail reception sponsorship,
please register and pay [HERE](#).

**For more information or to sign up for an exhibitor
space or sponsorship, please contact:**

MEGAN THOMAS
Director of Client Services
mthomas@beneschlaw.com

Nephrology and Dialysis



Dialysis & Nephrology DIGEST

Byonyks receives 510(k) clearance for new dialysis machine

Device maker Byonyks has received 510(k) clearance from the Food and Drug Administration for its X1 automated peritoneal dialysis (APD) cyclor.

Byonyks is only the third company to obtain marketing clearance from the FDA for an APD cyclor, according to Farrukh Usman, founder and CEO of Byonyks.

"Research shows that peritoneal dialysis (PD) preserves residual kidney function longer, and the therapy improves both quantity and quality of life," Usman said. "Unfortunately, 85% of Americans on dialysis do not receive PD. The FDA's clearance of X1 heralds a new era."

According to the U.S. Renal Data System, use of in-center hemodialysis, the most common form of kidney dialysis, has a 10% lower survival rate than peritoneal dialysis. "Our mission is not limited to putting a cyclor on the market; Byonyks' advanced development projects are aimed at significantly improving the clinical outcomes for PD patients and reducing and/or eliminating the many reasons for short tenures on this therapy," Rod Kenley, Byonyks' Chief Innovation Officer, said.

Currently, about 86% of the world's population who need dialysis have no access to it. "Byonyks is a dynamic company driven to improve the lives of our patients through transformative innovation that will improve global access to dialysis, improve biocompatibility, minimize metabolic impact, and reduce the risk of infection, all while decreasing the carbon footprint. That is a grand slam," Andrew King, MD, Byonyks' Chief Medical Officer, said.

For more information, visit www.byonyks.com.

Contact:

Senthil Kumar
VP of Business Development
senthil@byonyks.com

References:

<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K243371>

USRDS, <https://aspe.hhs.gov/sites/default/files/private/pdf/262046/AdvancingAmericanKidneyHealth.pdf> Page 25

2024 [Annual Data Report](#) | USRDS figure 9.11a,b

Dialysis & Nephrology DIGEST

Nephrology and Dialysis (cont'd)

Nation's Kidney Care Community Urges Legislators to Address Growing Kidney Disease Epidemic Impacting Nearly 40 Million Americans

WASHINGTON – [Kidney Care Partners](#) – the nation's leading kidney care multi-stakeholder coalition representing patient advocates, physician organizations, health professional groups, dialysis providers, researchers, and manufacturers – convened today on Capitol Hill to demonstrate support for policies that would ensure improved access to care, continued kidney innovation, and protection of coverage choices for those living with kidney disease.

“As the voice for the nation's kidney community, we are proud to support policies that strengthen care delivery, ensure patient choice, and spur much-needed innovation,” said Mahesh Krishnan, MD, MPH, MBA, Chair of Kidney Care Partners. “We look forward to working with lawmakers to create a sustainable, forward-looking kidney care system that benefits the 37 million Americans living with kidney disease.”

Currently, outdated and overly restrictive payment policies are limiting patients' access to 21st-century treatments and threaten to jeopardize Americans' access to innovation compared to other countries. These programs create immediate barriers to patient care while also discouraging investment in the next generation of kidney therapies. Meanwhile, payment to dialysis providers fails to accurately reflect increases in the cost of labor, supplies, and equipment needed to provide care. During meetings with lawmakers, KCP members highlighted the urgent need to resolve these immediate issues, while also discussing how comprehensive reform can modernize kidney care.

KCP advocates also voiced support for the Restore Protections for Dialysis Patients Act ([H.R. 2199](#) / [S. 1173](#)), which would reinstate vital safeguards for individuals living with kidney failure seeking to maintain their private health insurance coverage prior to transitioning to Medicare after the coordination period.

Additional information about KCP's fly-in and legislative priorities is [available here](#).

Nephrology and Dialysis (cont'd)

MAY 16, 2025

Benesch: OH bill banning non-compete agreements would have 'detrimental effect' on state businesses

The state Senate [bill](#) would prohibit noncompete agreements for all individuals providing services to employers, including employees, independent contractors, interns, volunteers and sole proprietors. It would eliminate restrictions on workers' ability to seek or accept employment elsewhere, regardless of time, geographic area or job similarity. It wouldn't allow agreements requiring departing workers to pay damages or other penalties upon termination and grant workers the right to sue employers for violations. Benesch Law suggests the bill in its current form won't pass the OH Senate, pointing out that it doesn't address the enforceability of non-solicitation agreements, protections for trade secrets or noncompete clauses related to business sales. Also, business associations and healthcare providers contend that noncompete agreements are essential for protecting investments in training and maintaining workforce stability. With business in OH's legislature tied up with budgetary debates, the noncompete bill will likely be reintroduced during the fall session, giving its sponsors time to meet with stakeholders on the legislation's final version.

SOURCE: Benesch Law

MAY 25, 2025

Northwest Kidney Centers says proposed cuts to Medicare, Medicaid 'matter of life or death' for patients

Rebecca Fox, President and CEO of Northwest Kidney Centers and the company's Chief Medical Officer, Dr. Matt Rivara, explain how Medicaid is essential for millions of Americans with chronic kidney disease, providing access to services like dialysis, transplants and preventive care. A House-approved bill now under Senate review proposes cutting Medicaid by \$715 billion, potentially leaving 8.6 million more people uninsured and severely impacting vulnerable kidney patients. They note the proposed changes, including shifting Medicaid to a block grant system and adding work requirements for recipients, could strip essential services from those who are too sick to meet those conditions. Data show Medicaid expansion leads to better outcomes for kidney patients, including reduced mortality and earlier transplant access. Northwest urges lawmakers to preserve Medicaid funding to protect both patient health and the sustainability of critical care providers.

Related: [Federal Cuts to Medicaid could end Medicaid expansion and affect hospitals in nearly every state](#) — The Commonwealth Fund
[Potential statutory pay-as-you-go effects of a bill to provide reconciliation pursuant to H. Con. Res. 14](#) — Congressional Budget Office

SOURCE: Seattle Times (sub. rec.)

Nephrology and Dialysis (cont'd)

MAY 7, 2025

AKF Kidney Action Summit urged Congress to pass legislation protecting living donors

Held prior to the passage of [HR 1](#) in the House, over three dozen American Kidney Fund (AKF) Ambassadors convened on Capitol Hill to advocate for policies supporting kidney disease patients and living organ donors. They urged lawmakers to co-sponsor [S.1552](#), which would prevent insurers from denying or altering coverage for individuals solely because they're living organ donors and to extend Family Medical Leave Act protections to donors. Additionally, the Ambassadors emphasized the importance of safeguarding Medicaid, a critical program for low-income individuals with end-stage renal disease.

SOURCE: American Kidney Fund

MAY 1, 2025

Members of Congress issue resolution demanding return of public consultations for HHS rules

Three Representatives, all Democrats, and three Senators (two Democrats and one Independent) introduced a [resolution](#) opposing a U.S. Department of Health and Human Services (HHS) policy to limit public notice and comment on proposed rules. The Congress members contend the change undermines decades of bipartisan precedent that allowed public input on regulations affecting healthcare, grants and benefits. They add that eliminating the process reduces transparency, excludes public voices and creates uncertainty for stakeholders. The resolution reaffirms the importance of public engagement in HHS rulemaking and preserves accountability in government decisions.

SOURCE: U.S. Congresswoman Lizzie Fletcher

MAY 6, 2025

MIPS improvement activities relating to DEI suspended by CMS; permanent deletion likely

CMS suspended eight improvement activities for the 2025 performance year under the Merit-based Incentive Payment System (MIPS). The activities include initiatives related to anti-racism plans, food insecurity protocols, LGBTQ+ patient care, community health engagement and COVID-19 data reporting. CMS plans to propose the removal of the activities in future rulemaking. CMS advises clinicians to discontinue participation in suspended activities and select alternative activities to receive MIPS credit.

SOURCE: American Hospital Association

June 2025

Nephrology and Dialysis (cont'd)

MAY 27, 2025

Report: U.S. import tariffs negatively affecting nephrology, urology market

The Trump Administration's tariffs are expected to impact medical devices manufactured outside the U.S., affecting nephrology and urology manufacturers like Fresenius Medical Care. About 9% of Fresenius' products are manufactured entirely in the U.S., which could lead to increased costs for goods. That could affect over half a million dialysis patients in the U.S., for whom delays or cost increases are detrimental. Dialyzers, a major product group for Fresenius, are fully manufactured in the U.S., potentially mitigating some tariff impacts.

SOURCE: GlobalData

MAY 22, 2025

Fresenius confirms financial outlook after posting strong financial results in Q1

Fresenius exceeded analysts' expectations for operating profit in Q1, posting a profit of \$743 million, 3% higher than the average estimate. Fresenius Medical Care, its former dialysis unit, also reported organic revenue growth across all segments and confirmed its 2025 guidance. Fresenius reduced its stake in FMC to 25% plus one share in March and aims for organic revenue growth of 4% to 6% for 2025. Meanwhile, FMC's Q1 financial results [show](#) a 3% YoY increase in operating income to \$5.4 billion and growth in operating income and net income of 35% and 113%, respectively.

SOURCE: Fresenius

MAY 12, 2025

DaVita beats Wall Street expectations for Q1 profit driven by dialysis demand

DaVita's earnings per share of \$2 topped analysts' estimates of \$1.95, as steady demand for dialysis services improved income. The company reports a 5% revenue increase in Q1 to \$3.2 billion. Despite challenges like rising operating costs, hurricane disruptions and a ransomware attack that compromised patient data, DaVita managed to reduce health benefits and operating expenses. The company also reaffirmed its 2025 profit guidance of \$10.20 to \$11.30 per share.

Related: [DaVita Inc. announces upsize, pricing of \\$1B senior notes offering](#)—DaVita

SOURCE: DaVita

Dialysis & Nephrology DIGEST

Nephrology and Dialysis (cont'd)

MAY 6, 2025

DaVita CEO defends AI investments; says technology is future of dialysis sector

DaVita, a leading provider in the dialysis industry, is focusing on technology solutions to enhance home dialysis care. CEO Javier Rodriguez highlighted the company's investment in artificial intelligence and interoperability to improve patient outcomes. Despite the potential benefits, only 15% of DaVita's patients opt for home dialysis, with half discontinuing annually due to clinical or lifestyle reasons. DaVita's efforts include a home monitoring system that allows nurses to oversee dialysis sessions remotely, aiming to address challenges in home care delivery.

SOURCE: Modern Healthcare (sub. rec.)

MAY 20, 2025

DaVita community care report showcases progress toward ESG goals

DaVita's [2024 Community Care Report](#) focuses on five areas:

1. Patient care: DaVita achieved a record number of kidney transplants, expanded its Kidney Smart education program and advanced home dialysis and value-based care initiatives;
2. Teammate engagement: High belonging scores, major employer recognitions and over 147,000 volunteer hours logged;
3. Environmental stewardship: DaVita reached key milestones, including significant water savings and progress toward 100% renewable energy matching by 2025;
4. Healthy communities: Free health screenings and over 100,000 medically tailored meals provided to food-insecure patients; and
5. Integrity & Accountability: DaVita reinforced its commitment to integrity with strong board independence and nearly universal completion of compliance training.

SOURCE: DaVita

Nephrology and Dialysis (cont'd)

MAY 12, 2025

Union's health benefits fund sues DaVita, Fresenius for conspiring to inflate treatment costs

The proposed class action from a UFCW local [claims](#) the companies carved up markets to avoid competition and engaged in coordinated price hikes not justified by market conditions. DaVita and Fresenius together control over 90% of the U.S. dialysis market. DaVita denied the allegations, calling them baseless, while Fresenius declined to comment. The lawsuit seeks damages for all entities that paid for outpatient dialysis services from the companies or their affiliates.

SOURCE: Reuters (sub. rec.)

MAY 1, 2025

DaVita facing two possible class actions relating to data stolen during cyberattack

A 2023 ransomware attack attributed to Russian cybercriminals compromised sensitive data belonging to DaVita patients. The breach led to the exposure of personal health information for thousands of individuals. In Colorado federal court, a [Las Vegas man](#) and two people from [Arizona and South Carolina](#) filed separate lawsuits seeking class action status. The plaintiffs allege DaVita failed to implement adequate cybersecurity measures, resulting in the unauthorized access and potential misuse of protected health information.

SOURCE: Law360 (sub. rec.)

MAY 13, 2025

Interwell Health recognized as among best places to work in healthcare

Modern Healthcare cited Interwell Health's commitment to employee satisfaction and organizational excellence in naming the company to its list of best places to work in healthcare for 2024. Interwell was recognized for offering benefits such as 100% remote work for most positions, tuition reimbursement, 401(k) matching, a paid volunteering day and health resources, including mental health and fertility benefits. The company also supports organ donation by providing up to eight weeks of paid leave for employees who donate and established eight Employee Resource Groups to enhance employee engagement and connection.

SOURCE: Interwell Health

Nephrology and Dialysis (cont'd)

APRIL 29, 2025

North Carolina nephrology practice cited for innovative value-based kidney care

Charlotte-based [Metrolina Nephrology Associates](#) was recognized with a 2024 Innovator Award for its implementation of the Kidney Care Choices (KCC) model. Collaborating with Interwell Health, Metrolina established the Charlotte Kidney Contracting Entity to enhance care coordination and improve outcomes for patients with chronic kidney disease and end-stage renal disease. The partnership focused on the strategies of:

- Leveraging data-driven insights to identify at-risk patients;
- Expanding care coordination through interdisciplinary teams; and
- Improving quality measures such as optimal dialysis starts and depression screening.

SOURCE: Interwell Health

APRIL 28, 2025

Healthy.io acquires Labrador Health to enhance at-home kidney diagnostics portfolio

Labrador Health specializes in quantitative urine testing using microfluidics and computer vision, enabling lab-grade results at home. The integration with [Healthy.io](#) will spur the development of the first quantitative home-based albumin-to-creatinine ratio test, targeting a 2026 launch. The acquisition aligns with Healthy.io's mission to expand access to early chronic kidney disease detection through smartphone-powered technology.

SOURCE: Healthy.io

APRIL 30, 2025

Novartis' \$800M acquisition of Regulus includes drug to treat ADPKD

Novartis' total investment in Regulus Therapeutics could reach \$1.7 billion if certain benchmarks are met. Regulus-developed farabursen completed a Phase 1B trial in patients with autosomal dominant polycystic kidney disease (ADPKD) and the \$800 million it's getting upfront from Novartis will support a Phase 3 study as the partners seek expedited approval. Following the transaction, Regulus will be a wholly-owned subsidiary of Novartis.

SOURCE: Novartis

Nephrology and Dialysis (cont'd)

MAY 6, 2025

Study underscores significant electricity costs for patients with home dialysis units

A study conducted by Indiana University, the Regenstrief Institute, the University of Pennsylvania and Yale University reveals that durable medical equipment (DME) like oxygen concentrators, CPAP machines and peritoneal dialysis devices significantly increase household electricity costs. Annual electricity expenses for these devices range from \$120 to over \$700, depending on the device type, usage frequency and regional electricity rates. In some states with higher electricity costs, expenses can elevate a household's monthly energy bill by up to 40%. The researchers point out this financial burden is particularly challenging for individuals already vulnerable due to chronic health conditions, adding Medicare and Medicaid programs don't cover electricity costs, potentially limiting access to DMEs.

SOURCE: Regenstrief Institute

APRIL 28, 2025

ASN introducing centers of excellence to serve as models for home dialysis care

The American Society of Nephrology is piloting a Centers of Excellence in Home Dialysis program to recognize healthcare organizations that meet national standards in home dialysis care. The program aims to improve patient outcomes and expand access to home dialysis in North America. Despite a slight increase in home dialysis uptake, barriers such as fear and lack of awareness persist. The program will begin this year and is supported by [Vantive](#), formerly Baxter's kidney care unit.

SOURCE: American Society of Nephrology

APRIL 23, 2025

American Kidney Fund identifies significant racial, ethnic disparities in progression, treatment of ADPKD

The American Kidney Fund (AKF) says Black and Hispanic/Latino patients with autosomal dominant polycystic kidney disease (ADPKD) tend to experience kidney failure earlier and are less likely to receive early referrals for kidney transplantation compared to white patients. Additionally, these patients often face longer wait times for kidney transplants and have higher risks of transplant failure due to factors like longer dialysis durations and organ mismatches. The AKF states addressing these disparities requires standardized care protocols, bias training for healthcare providers and increased patient advocacy and education.

SOURCE: American Kidney Fund

VAC, ASC and Office-Based Labs

MAY 24, 2025

Interventional radiologists call for higher Medicare reimbursements for high-cost disposables

The Society of Interventional Radiology (SIR) and other medical societies are advocating for federal legislation to create a Medicare payment system that would reimburse high-cost medical supplies separately from the Medicare Physician Fee Schedule in community settings. The resolution would address the issue of Medicare reimbursements not covering the true costs of supplies, particularly for non-facility services provided at ambulatory surgical centers. Data from CMS indicates that in 2025, 300 non-facility services will be reimbursed at rates below their direct costs, highlighting the financial challenges faced by these outpatient facilities.

SOURCE: Radiology Business

MAY 1, 2025

Medicare reimbursement for coronary revascularization at ASCs improving, but uptake remains low

Medicare began reimbursing percutaneous coronary interventions (PCI) at ASCs in 2020, but through 2022, only 1.8% of outpatient PCIs were performed at free-standing ASCs. Despite ASCs being more prevalent in low-income communities, there was evidence of patient selection for PCI, with fewer high-risk patients. Clinical outcomes showed comparable safety to hospital outpatient departments, with ASCs having lower rates of hospital readmissions and acute myocardial infarctions, although higher rates of repeat PCI raised quality concerns. Experts note the regional and regulatory influences on ASC adoption and emphasize the need for careful expansion of services without encroaching into high-risk territory. Data collection and the development of ASC-specific quality benchmarks are considered critical for the safe growth of the care model.

SOURCE: MedPage Today (sub. rec.)

Dialysis & Nephrology DIGEST

For more information regarding our nephrology, dialysis
and office-based lab experience, or
if you would like to contribute to the newsletter, please contact:

Jake Cilek

jcilek@beneschlaw.com | 312.624.6363

Scott Downing

sdowning@beneschlaw.com | 312.624.6326

Jason Greis

jgreis@beneschlaw.com | 312.624.6412

Advertise with Us!

To advertise in Benesch's Dialysis & Nephrology Digest, contact Lauren Luna at
lluna@beneschlaw.com or 216.363.6199.